CPT 0206U Discern™ PKCε Skin Assay Reimbursement

CPT code 0206U is a Proprietary Laboratory Analyses (PLA) code that identifies the Discern™ test by NeuroDiagnostics, a laboratory assay that uses morphometric imaging and protein kinase C–epsilon (PKCε) biomarker measurement on cultured skin specimens to assist in identifying Alzheimer disease. As a PLA code, 0206U is tied to a single manufacturer's proprietary test, which has implications for coding specificity, payer coverage determinations, and lab billing workflows nationally. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what CPT code 0206U represents clinically and operationally, how it typically fits into diagnostic pathways for suspected Alzheimer disease, and which major payers are relevant for coverage considerations. The publication outlines common payer interactions, typical site-of-service patterns for specimen collection and laboratory testing, and the policy and billing context that affects adoption of PLA-coded assays. It also summarizes available benchmarks and areas where policy updates or payer guidance may affect claims processing and lab reimbursement. Data not available in the input is noted where applicable.

Billing Code Overview

CPT code 0206U is a Proprietary Laboratory Analyses (PLA) code that describes the Discern™ test by NeuroDiagnostics. The test analyzes a cultured skin specimen using morphometric imaging and measurement of the protein kinase C–epsilon (PKCε) biomarker to aid in identification of Alzheimer disease. This code represents a single, manufacturer-specific laboratory assay provided by NeuroDiagnostics.

Service type: Laboratory diagnostic assay involving cultured skin specimen analysis
Typical site of service: Clinical laboratory or specialized diagnostic laboratory (specimen collection may occur in outpatient clinic or ambulatory setting)

Clinical Context

A typical patient is an older adult with progressive cognitive decline, memory loss, or clinical features concerning for early Alzheimer disease evaluated in a neurology or memory clinic. The patient undergoes a skin punch biopsy to obtain a small cultured skin specimen. The specimen is sent to NeuroDiagnostics for the proprietary Discern™ assay (0206U), which includes morphometric imaging and protein kinase C–epsilon (PKCε) biomarker measurements to aid in identifying Alzheimer disease pathology. The clinical workflow: the neurologist or geriatrician documents cognitive exam findings and orders the test; a dermatology or neurology clinician performs the skin punch biopsy during an outpatient visit (typical site of service: outpatient physician office or ambulatory surgical center; laboratory processing occurs at the proprietary testing laboratory); the specimen is shipped under chain-of-custody to the vendor laboratory; the laboratory performs culture, morphometric imaging, and PKCε assays and reports a result that is incorporated into the patient’s diagnostic evaluation and care plan. Indications include diagnostic clarification in patients with suspected Alzheimer disease, particularly when noninvasive blood or cerebrospinal fluid biomarkers are inconclusive or unavailable.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Standard reporting when no modifier applies

Taxonomy Code	Specialty	Notes
207RH0000X	Neurology	Neurologists order and interpret dementia diagnostic testing
207P00000X	Psychiatry	Geriatric psychiatrists involved in cognitive disorder evaluation
207N00000X	Geriatric Medicine	Geriatricians managing dementia evaluation and ordering tests
207L00000X	Dermatology	Dermatologists frequently perform skin punch biopsies for specimen collection
2084P0800X	Clinical Laboratory	Laboratory directors and specialized testing labs performing the assay

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G30.0`	Alzheimer disease with early onset	Indicative of Alzheimer pathology in younger patients where confirmatory biomarker testing may be sought
`G30.1`	Alzheimer disease with late onset	Common diagnostic indication for biomarker testing to support clinical diagnosis in older adults
`G30.9`	Alzheimer disease, unspecified	Used when Alzheimer disease is suspected but not otherwise specified; test may support diagnosis
`F02.80`	Dementia in other diseases classified elsewhere without behavioral disturbance	Dementia phenotype requiring further evaluation including biomarker testing
`F03.90`	Unspecified dementia without behavioral disturbance	Symptom-based diagnosis where ancillary testing can aid in etiologic clarification

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0212U`	Proprietary laboratory analysis; amyloid beta oligomer assay (example PLA code)	Other proprietary biomarker assays may be ordered in parallel or as alternative molecular diagnostics in dementia evaluation
`11102`	Tangential biopsy of skin, single lesion; excision less than 1.1 cm	Procedure code for skin biopsy techniques that may be used to obtain the specimen prior to laboratory testing
`87070`	Culture, bacterial; any source, aerobic, with isolation and presumptive identification of colonies	General microbiology culture code; included here as an example of laboratory processing codes that might accompany specimen handling (not specific to proprietary assay)
`88342`	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain	Ancillary tissue-based testing that may be performed on skin specimens in other diagnostic workflows

OpenPayer

Summary & Overview

CPT 0206U: Discern™ Skin Specimen PKCε Assay for Alzheimer Disease